Media Center
In the media
AbilityPharma rises 1.2M euros with the biggest round of Capitall Cell
December 7, 2018
10/12/2018
AbilityPharma recibe su tercera designación de medicamento huérfano por la FDA
Expansión
08/11/2018
TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech
Innovaspain
26/09/2018
AbilityPharma starts the Phase 2 with the anticancer drug ABTL0812
Diari de Sabadell
06/12/2016
Start of a clinical trial with a new drug for lung and endometiral cancer
La Vanguardia online
22/11/2016
European support to the oncology investigation
La Vanguardia
08/04/2015
Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma
Siege to cancer from Bellaterra
L'Econòmic - El Punt Avui
19/02/2013
The biomedical company Ability Pharmaceuticals obtains financing for a pioneering treatment for pancreatic and lung cancer in humans
LATEST NEWS
05.12.2018
News
AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018
News
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018
News
Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018
News
At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018
News
AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017
News
AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017
News
Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017
News
Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017
News
Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
